Physician- and Patient-based Barriers to NGS Testing (NCT07209176)
A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
- Provider-level and patient education at end of study (OTHER)
- Provider-level and patient-level (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 955-0231
Email: chm@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.